AlpInvest's $1.7 Billion Continuation Vehicle Fund: What a 393% Jump Signals

TL;DR: Carlyle's AlpInvest arm closed AlpInvest Atom Fund II (AAF II) at a $1.7 billion hard cap on July 15, 2026, a 393% jump from its 2023 predecessor fund, according to Alternatives Watch. The fund buys into single-asset continuation vehicles, deals where a private equity firm moves a company it already owns into a new vehicle instead of selling it outright. That jump in three years tells you how fast this corner of private equity is growing, and why you should understand the mechanics before anyone asks you to roll your money into one.

I've watched a lot of private equity structures go from niche to mainstream. Few have moved as fast as the continuation vehicle. Carlyle's secondaries arm, AlpInvest, just put a number on that speed: $1.7 billion, raised for a strategy that didn't exist as a dedicated fund line until 2023, when its predecessor closed at a fraction of the size.

Let's define the term before we go further, because if you're an accredited investor getting calls about "continuation vehicle opportunities," you need the vocabulary before you need the pitch deck.

What a continuation vehicle actually is

A continuation vehicle (also called a continuation fund) lets a private equity firm (the general partner, or GP) move a company it already owns out of an aging fund and into a brand-new fund vehicle. The GP keeps running the company. The old fund's limited partners (LPs, the investors who committed capital to that fund) get a choice: cash out at the negotiated price, or roll their stake into the new vehicle and stay invested alongside fresh capital that the GP raises for the deal.

Why does this happen? Most PE funds have a contractual lifespan, typically 10 to 12 years. If a GP still believes in a portfolio company's upside after year nine, but the fund's clock is running out, the GP can't just hold on. A continuation vehicle solves that problem. It's a legal mechanism for extending ownership of a specific asset beyond the original fund's life, while giving the people who backed that fund an exit if they want one.

Single-asset continuation vehicles (SACVs), the flavor AAF II specializes in, do this for one company at a time, usually a "trophy" holding the GP considers its best performer. Multi-asset continuation vehicles bundle several portfolio companies together. Both types put new secondary buyers, like AlpInvest, on the other side of the trade from the fund's original LPs.

The deal mechanics behind AAF II

According to Carlyle's own announcement, AAF II closed at its $1.7 billion hard cap, well above its original $1 billion target. It's the second dedicated fund in AlpInvest's "Atom" series, following a smaller 2023 predecessor. Combined with AlpInvest's evergreen secondaries vehicles and related sidecar capital, the firm now has roughly $7 billion in total capacity earmarked specifically for single-asset continuation vehicle transactions.

The fund's mandate: buy meaningful equity stakes in high-quality, sponsor-backed companies moving into single-asset continuation vehicles, mostly in North America and Western Europe. AlpInvest isn't a generalist here. Chris Perriello, the firm's global head of secondaries, and Julian Rampelmann, its head of single-asset secondaries, run a team that's been doing this specific trade since 2018: 31 transactions and roughly $7 billion committed to date, per the firm's release, also reported by Private Equity Wire.

Carlyle AlpInvest overall manages roughly $107 billion, spread across secondaries, portfolio finance, and primary fund commitments. The continuation vehicle strategy is a sliver of that book, but it's the sliver growing fastest, and it plugs into a broader platform: the firm says it draws on 25 years of GP relationships and proprietary data on tens of thousands of private companies to underwrite these deals. That's the pitch to sponsors: AlpInvest isn't just capital, it's a repeat counterparty that GPs will work with again.

Why this number matters more than it looks

A 393% increase in fund size over three years isn't organic growth. It's a market inflection. Here's the context that makes AAF II legible as a signal rather than a one-off fundraise.

Global secondary market volume, the broader category covering both LP-led sales (an investor selling its fund stake to another investor) and GP-led deals like continuation vehicles, hit roughly $226 billion in 2025, a record, according to Evercore data cited by Belasko's analysis of the continuation fund market. GP-led volume within that made up about $106 billion, up roughly 50% year over year. Jefferies' January 2026 secondary market review put the 2025 GP-led figure even higher, near $115 billion, and calculated that continuation vehicles specifically accounted for about 89% of all GP-led volume, per CAIA's research on the continuation vehicle boom.

Scale is climbing too. GCM Grosvenor's research found that average continuation vehicle size rose about 15% year over year to roughly $1 billion in 2025, and the number of deals over $1 billion jumped 57% compared to 2024, according to the firm's analysis of which platforms are positioned to succeed in this market. That same research notes 83% of the top 100 global buyout sponsors have used a continuation vehicle at least once, and continuation vehicles now represent about 15% of total sponsor-backed exit value, up from 8% in 2021.

Put plainly: continuation vehicles have gone from a workaround for stuck funds to a standard exit lane that sits alongside a sale to another company (strategic exit), a sale to another PE firm, and an IPO. When the M&A market is slow and IPO windows keep slamming shut, which describes a lot of the environment since 2022, GPs increasingly default to the continuation vehicle instead of waiting. Coller Capital's own market commentary states it directly: whether M&A or IPO markets reopen in 2026 "doesn't really matter" to continuation vehicle demand, because GPs are using the structure for strategic reasons, preserving assets under management and holding onto winners, not just as a liquidity patch. That's the sentence that should stick with you. This isn't cyclical anymore. It's structural.

AlpInvest raising 4x more capital for the same strategy in three years is that macro trend showing up in one firm's numbers. And AlpInvest isn't alone chasing this pool of capital. Dedicated secondaries dry powder is enormous, but so is deal flow, which keeps pricing and access competitive for firms like AlpInvest that specialize in this specific niche.

The part sponsors don't lead with: the conflict is structural

Here's where I put on my skeptic hat, because this deal type has a feature that's easy to gloss over in a press release: the GP sits on both sides of the trade.

Think about what actually happens in a continuation vehicle transaction. The general partner who manages the old fund is the same party negotiating the sale price of the asset moving into the new vehicle. That GP will also manage the asset in the new vehicle, and keep collecting management fees and carried interest (the GP's share of profits, typically 20%) on it for years longer than the original fund would have allowed. The GP isn't a neutral referee setting a fair price between a buyer and seller. The GP is the seller, the buyer's asset manager, and often has skin in structuring the new fund's incentives, too.

That's not automatically dishonest. But it's a textbook conflict of interest, and the industry itself has been sounding alarms on it for years. ILPA (the Institutional Limited Partners Association, the trade group representing LPs) published guidance back in 2023 explicitly because "conflicts are inherent as GPs sit on both sides of the deal," in the group's own language from its continuation fund best-practices guidance. ILPA has since drafted an updated version of that guidance in 2026, specifically because continuation vehicles have gotten more frequent and more complex since the first round of recommendations, and existing gaps in disclosure and process integrity haven't fully closed.

Where does the conflict actually bite? A few places worth naming specifically:

• Pricing. The GP has more information about the asset than anyone else in the room. If the sale price is too low, existing LPs who sell out get shortchanged. If it's too high, new investors in the continuation vehicle (plus any LPs who roll over) overpay, and the GP still collects fees either way.
• Carried interest crystallization. Moving an asset into a new vehicle can let the GP "crystallize" (lock in and collect) carried interest on paper gains before the asset is actually sold to a third party. ILPA's guidance recommends GPs roll 100% of that crystallized carry into the new vehicle to keep incentives aligned, but that's a recommendation, not a legal requirement, and not every deal follows it.
• The "status quo" option. ILPA's guidance says existing LPs must be offered a true no-change rollover option, same economic terms as the original fund, not just a binary cash-out-or-accept-new-terms choice. LPs who don't understand they have this option, or whose GP doesn't clearly offer it, can end up accepting worse terms than they had to.
• Advisor independence. GPs typically hire an outside advisor to run the sale process and solicit competing bids. That advisor is picked and paid by the GP, which is the party with the conflict in the first place.

None of this means continuation vehicles are a scam. AlpInvest's model, a dedicated team, repeat GP relationships, proprietary underwriting data, exists precisely because sophisticated secondary buyers know how to price around these conflicts when they're the ones buying in fresh. The problem is asymmetric: AlpInvest has an underwriting team built for exactly this. Most individual LPs, and certainly most accredited investors evaluating a rollover election for the first time, do not.

What to check before you roll into a continuation vehicle

If you're an LP in a fund that's proposing a continuation vehicle, or an accredited investor being pitched on buying into one as new capital, here's the list I'd work through before signing anything.

Question	Why it matters
Did the LP Advisory Committee (LPAC) review and approve the transaction, including the conflicts?	The LPAC is supposed to be the independent check on GP self-dealing. No LPAC review is a red flag.
Was the asset's price set through a competitive process with an independent advisor, or a fairness opinion from a third-party appraiser?	A single-bidder or GP-controlled valuation process has no external check on price.
Is a true "status quo" rollover option on the table — same fees, same terms as the original fund?	ILPA guidance says this should always be offered. If it isn't, ask why.
What percentage of the GP's crystallized carried interest is rolling into the new vehicle alongside your money?	If the GP is cashing out its own carry while asking you to roll over, that's a misalignment worth flagging.
How much time do you actually have to decide?	ILPA recommends at least 20 business days. Rushed timelines favor the GP, not you.
What happens if you don't make an election at all?	Under ILPA guidance, non-response should default to a sell election — know that before you let a deadline pass.
What are the new vehicle's fee terms compared to the old fund , management fee, carry, hurdle rate?	New vehicles sometimes reset fee terms in the GP's favor for the extended hold period.
Who else is buying into the new vehicle, and has the sponsor done continuation vehicles before?	A repeat, disciplined buyer like AlpInvest brings underwriting rigor. A first-time or thinly capitalized buyer brings execution risk.

Ask for the disclosure document in writing. ILPA rolled out a standardized Continuation Fund Disclosure Template in 2026 aimed at making these comparisons easier across deals. If your GP can't produce something close to that level of detail, treat that as information too.

The bigger picture is one I keep coming back to. Private Equity International's GP-led secondaries research notes the market broke $100 billion in annual GP-led volume for the first time in 2025 and continues broadening in deal types and participants, including new capital from wealth platforms and insurance investors, money that increasingly touches accredited investors and family offices, not just institutional LPs. That's the direction this market is moving: down-market, toward investors who may not have an in-house team built to catch the conflicts institutional LPs have spent a decade learning to spot. AlpInvest's $1.7 billion fund is a professional buyer's bet that the trade is attractive when you're the one setting terms. If you're on the other side of that table, do the homework the professionals do, or skip the deal.

Related on AIN: See StepStone's self-storage continuation vehicle. the VC secondaries market in Europe. GP financing and fund economics. HarbourVest's $4.75B co-investment program.

Author Disclosure: Jeff Barnes, MBA has no personal position in any company, fund, or platform named in this article. Angel Investors Network has no current commercial relationship with any party mentioned. AIN provides marketing and education services, not investment advice. Past performance does not guarantee future results. All investments involve risk, including loss of principal.